Quick Takeaways
- Teoxane SA filed SCHEDULE 13D/A for Revance Therapeutics, Inc. Common Stock, par value $0.001 per share (RVNC).
- Disclosed ownership: 6.2%.
- Date of event: 30 Jan 2025.
Teoxane SA - 30 Jan 2025 SCHEDULE 13D/A Report for Revance Therapeutics, Inc. Common Stock, par value $0.001 per share (RVNC)
- Filing Manager
- Teoxane SA
- Reporting Manager
- Teoxane SA
- Symbol
- RVNC
- Shares outstanding
- 105,658,065 shares
- Disclosed Ownership
- 6,550,800 shares
- Ownership
- 6.2%
- Form type
- SCHEDULE 13D/A
- Filing time
- 30 Jan 2025, 09:01:04 UTC
- Date of event
- 30 Jan 2025
- Previous filing
- 06 Jan 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Teoxane SA disclosed 6.2% ownership in Revance Therapeutics, Inc. Common Stock, par value $0.001 per share (RVNC) on 30 Jan 2025."
What Changed
- Previous schedule filing date: 06 Jan 2025.
- Current filing was accepted on 30 Jan 2025, 09:01.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Teoxane SA | 6.2% | 6,550,800 | 6,550,800 | 0 | /s/ Patrice Calvayrac | Patrice Calvayrac/ Chief Financial Officer | 0001992112 |